Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

Novavax Inc. closed 60.53% below its 52-week high of $17.81, which the company reached on July 26th.

Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

In the real world setting, when patients have to pay for their drugs out of their own pocket and without a rigorous reminder, ...

Provincial health officials recommend that Nova Scotians 65 years and older get a dose of Covid-19 vaccine this spring. The ...

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

Although vaccines may have a tougher time winning the endorsement of the CDC's Advisory Committee on Immunization Practices ...

COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring “razor ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings ...